Publication | Closed Access

Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling

Medicinal ChemistryTranslational Pharmacology5-Hydroxytryptamine 4-ReceptorMedicineMechanism Of ActionPharmacotherapyPharmacologyRadiation OncologyCell SignalingPotential Antitumor DrugDrug DiscoveryJak-stat Signaling Pathway